Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

IMMUNOTHERAPY with chemotherapy is emerging as a new standard first-line treatment in advanced endometrial cancer (EC). In an insightful session ... Recently, dostarlimab and pembrolizumab showed ...

Study Rundown: Cervical cancer is the fourth most common cancer affecting women worldwide. Previous trials have shown that adding pembrolizumab, an anti-PD1 antibody, to chemoradiotherapy may improve ...

Adding pembrolizumab to adjuvant chemotherapy in the first-line setting improved disease-free survival (DFS) in patients with high-risk endometrial cancer who have mismatch repair–deficient ...

and can be protective against conditions like uterine hyperplasia and endometrial cancer. If a woman still wants the benefits of contraception from an IUD, she can also consider using the ParaGard ...

Lenvatinib (Lenvima) given with pembrolizumab (Keytruda ... In the interview, Llovet, director of the Liver Cancer Program and professor of medicine in the Division of Liver Diseases at the Icahn ...

KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...

or systemic therapy for cervical cancer. Patients were randomized (1:1) to receive either: Endometrial carcinoma begins in the inner lining of the uterus, which is known as the endometrium, and is the ...

827 patients with advanced endometrial cancer who had progressive disease after platinum-based chemotherapy were randomly assigned to receive lenvatinib plus pembrolizumab (411 patients ...

Findings seen in combination with chemotherapy following surgery in patients with curative intent. HealthDay News — Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in ...

MONDAY, Oct. 21, 2024 (HealthDay News) — Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer after surgery with curative intent, ...